drugset / Trial / NCT00782184

Ezetimibe/Simvastatin (10 mg/40 mg) vs. the Doubling of Atorvastatin in High Risk Participants (MK-0653A-134 AM1)(COMPLETED)

NCT00782184

Phase 3 Completed 250 enrolled Organon and Co
RandomizedParallel-groupDouble-blindTreatment

Summary

Participants currently taking atorvastatin 20 mg will be switched to either atorvastatin 40 mg or ezetimibe/simvastatin 10 mg/40 mg (10/40). After 6 weeks of treatment, the percent reduction in low-density lipoprotein cholesterol (LDL-C) will be assessed and compared between the two treatment groups.

Timeline

Start
2008-11
Primary completion
2010-09
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atorvastatin Small molecule 20 mg
Comparator Atorvastatin Small molecule 40 mg
Subject Ezetimibe Unknown 10 mg
Subject Simvastatin Small molecule 40 mg

Indications